Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
Submission to FTC on the Role of Intellectual Property
A Chinese twist in the tale involving Hepatitis C drug Sofosbuvir
Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry
Would reforming the U.S. patent system help to lower drug prices?
China Patent Challenge Compels Gilead to Withdraw Key Patent Claims on Sofosbuvir Base Compound, Opening Life-Saving Hepatitis C Treatment Access for Millions
Reality check on PBMs and drug costs
Patent abuse driving high drug prices, non-profit claims
Brainstorm Health: BeiGene IPO, Amerisource CEO on Amazon, California Data Privacy Law
Axios Vitals: Patents = profits (Article 3)
Report: Hundreds of Patents on America’s Top Selling Drugs are Triggering Price Hikes and Blocking Competition